| Date | Time | Source | Headline | Symbol | Company |
| 05/02/2024 | 2:07PM | iHub Newswire | FeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | | |
| 12/21/2023 | 3:32PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 12/05/2023 | 6:26PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 12/01/2023 | 11:49AM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 11/16/2023 | 4:55PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 10/23/2023 | 1:56PM | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 10/05/2023 | 9:01PM | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 10/05/2023 | 4:21PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 09/15/2023 | 3:42PM | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 09/11/2023 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 08/15/2023 | 5:53PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 08/11/2023 | 4:06PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 08/10/2023 | 9:29AM | Business Wire | Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 08/08/2023 | 4:23PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/31/2023 | 9:32AM | Business Wire | Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/28/2023 | 8:23PM | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/28/2023 | 5:10PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/27/2023 | 5:20PM | Business Wire | Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/17/2023 | 6:02PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/17/2023 | 6:00PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/13/2023 | 5:27PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/13/2023 | 5:09PM | Business Wire | Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/06/2023 | 4:39PM | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/03/2023 | 5:30PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/03/2023 | 4:01PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/30/2023 | 4:01PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/30/2023 | 10:46AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/30/2023 | 10:46AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/30/2023 | 9:16AM | Business Wire | Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/16/2023 | 5:23PM | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |